Clinical research
The primary endpoint of the trial will be prevention of symptomatic COVID-19 disease, with key secondary endpoints including prevention of severe COVID-19, defined as hospitalization, and prevention of infection by SARS-CoV-2.
Results from the Phase III JADE TEEN study of abrocitinib in teen patients, ages 12 to 18, who have moderate to severe atopic dermatitis and were on background topical therapy, showed improvements in skin clearance, disease extent and a reduction in severity.
In an interview this morning with CNN, Dr. Anthony Fauci said the government will help finance Phase III studies of three vaccine candidates.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer’s Drug
Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
KEYNOTE-361 is evaluating Keytruda alone and in combination with chemotherapy compared to chemotherapy alone, the current standard of care, for first-line treatment of advanced or metastatic urothelial carcinoma.
On Monday, Sarepta Therapeutics announced positive results from a small study of SRP-9003, its gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E).
The results of Lumasiran were presented at the European Renal Association-European Dialysis and Transplant Association International Congress.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
Roxadustat was non-inferior to Aranesp in hemoglobin levels during the first 24 weeks of treatment, which was the trial’s primary endpoint.
PRESS RELEASES